Angiotensin 1-7 significantly reduces diabetes-induced leukocyte recruitment both in vivo and in vitro.
Explore this paper's citation graph
Summary
The findings emphasize the potential utility of ACE2/Ang1-7/Mas repletion as a strategy to reduce diabetes-induced atherosclerosis and reduce vascular hypertrophy and the other molecular changes due to diabetes.
- Type
- article
- Published
- 2016-01-01
- Cited by
- 16
- References
- 59
- Access
- Open access
- OpenAlex
- https://openalex.org/W2180975891
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32085717
Keywords
Diabetes mellitus, In vivo, Streptozotocin, Medicine, Saline
References
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
- Atherosclerosis is an Inflammatory Disease
- Chemical Communication between Heart Cells is Disrupted by Intracellular Renin and Angiotensin II: Implications for Heart Development and Disease
- Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo.
- Innate immunity, through late complement components activation, contributes to the development of early vascular inflammation and morphologic alterations in experimental diabetes.
- The deleterious effect of high concentrations of D-glucose requires pro-inflammatory preconditioning
- Angiotensin-(1-7) Attenuates Angiotensin II-Induced ICAM-1, VCAM-1, and MCP-1 Expression via the MAS Receptor Through Suppression of P38 and NF-κB Pathways in HUVECs
- Angiotensin II and the pathophysiology of cardiovascular remodeling.
- Flavonoids inhibit high glucose-induced up-regulation of ICAM-1 via the p38 MAPK pathway in human vein endothelial cells.
- Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.
- Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.
- Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats.
- Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.
- TRAIL Modulates the Immune System and Protects against the Development of Diabetes
- A major role for VCAM-1, but not ICAM-1, in early atherosclerosis.
- Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7).
- Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.
- Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells.
- Angiotensin-converting enzyme 2 is an essential regulator of heart function
- Chemical communication between cardiac cells is disrupted by high glucose: implications for the diabetic heart.
Cited by
- Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
- ACE2 and the Homolog Collectrin in the Modulation of Nitric Oxide and Oxidative Stress in Blood Pressure Homeostasis and Vascular Injury
- Anti‐inflammatory action of angiotensin 1‐7 in experimental colitis may be mediated through modulation of serum cytokines/chemokines and immune cell functions
- Modulation of leucocytic angiotensin-converting enzymes expression in patients maintained on high-permeable haemodialysis
- The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7)
- Efficacy of lanthionine‐stabilized angiotensin‐(1–7) in type I and type II diabetes mouse models
- Ang-(1-7)/ MAS1 receptor axis inhibits allergic airway inflammation via blockade of Src-mediated EGFR transactivation in a murine model of asthma
- Liver Disease - A Concern in SARS-COV2 Infection
- Research Progress of Alzheimer’s Disease Therapeutic Drugs: Based on Renin-Angiotensin System Axis
- Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges
- Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Targets
- Restoring Epigenetic Reprogramming with Diet and Exercise to Improve Health-Related Metabolic Diseases
- ACE2 PET in healthy and diseased conditions
- Possible role of LCZ696 in atherosclerosis: new inroads and perspective
- Myristoylated Cathelicidin-DM Fused With ANG1-7: A Novel Self-Assembling Antimicrobial Peptide for the Treatment and Mechanism of Diabetic Infected Wounds
Related papers
- MicroRNA-345-3p is a potential biomarker and ameliorates rheumatoid arthritis by reducing the release of proinflammatory cytokines
- Dihydrocapsaicin suppresses proinflammatory cytokines expression by enhancing nuclear factor IA in a NF-κB-dependent manner.
- Effects of Proinflammatory Cytokines in the Heart
- Induction of inducible nitric oxide synthase and proinflammatory cytokines expression by o,p'-DDT in macrophages.
- Proinflammatory and Anti-inflammatory genes in stroke pathogenesis.
- Pro-inflammatory cytokines mediate GPCR dysfunction
- Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1.
- Effects of Cytokines and Endotoxin on the Intracellular Growth of Bacteria
- In Response.
- Central Proinflammatory Cytokines and Pain Enhancement